Introduction
============

Bladder cancer is one of the most frequently occurring neoplasms in men. The established risk factors for bladder cancer include cigarette smoking, occupational exposure to certain chemical carcinogens such as aromatic amines and uptake of drugs such as phenacetin and cyclophosphamide. These carcinogens can cause DNA damage, introducing bulky adducts, crosslinks and single or double strand breaks \[[@B1]\]. Tobacco smoke and occupational exposures are the major risk factors in Western countries, whereas schistosoma hematobium infection is the major etiologic factor in developing countries, particularly in Africa and the Middle East \[[@B2]\]. Although many people are exposed to the risk factors, only a fraction of exposed individuals will develop bladder cancer, suggesting an individual susceptibility to the effects of carcinogens.

The xeroderma pigmentosum complementation group C (XPC) protein is involved in the recognition and initiation of the global genome repair pathway of nucleotide excision repair. XPC binds to HR23B to form the stable XPC-HR23B complex, which recognizes and binds to damaged DNA \[[@B3]\]. XPC gene is located at chromosome 3p25 and contains 16 exons and 15 introns, which is one of the eight core genes (XPA, XPB, XPC, XPD, XPE, XPF, XPG and ERCC1) in the NER pathway. Polymorphisms in XPC gene have been evaluated as risk factors in bladder cancer in a number of epidemiological studies, however the conclusions were controversial. Therefore, in the present study, we performed this meta-analysis of all the published studies on bladder cancer to draw a more precise estimation of this association.

Methods
=======

Literature search
-----------------

A comprehensive search was conducted through re.searching MEDLINE, EMBASE, PubMed, Web of Science, China Biomedical Literature database (CBM) and China National Knowledge Infrastructure (CNKI) databases before June 2013. Relevant publications were searched using follow terms: "XPC", "Xeroderma pigmentosum group C", "polymorphism", "variant", "bladder cancer", "bladder tumor", "bladder carcinoma" and "bladder neoplasm". We evaluated all associated publications to retrieve the most eligible literatures. The reference lists of reviews and retrieved articles were hand searched at the same time. We did not include abstracts or unpublished reports. When overlapping data of the same patient population were included in more than one publication, only the most recent or complete study was used in this meta-analysis.

Inclusion and exclusion criteria
--------------------------------

Studies included in our meta-analysis had to meet the following inclusion criteria: (1) evaluate the association between XPC Lys939Gln polymorphism and bladder cancer risk; (2) case--control designed studies; (3) sufficient information to estimate odds ratios (ORs) and their 95% confidence intervals (CIs). Studies were excluded if one of the following existed: (1) no control population; and (2) duplicate of previous publication.

Data extraction
---------------

Information was carefully assessed and extracted from all eligible publications according to the inclusion criteria by two investigators independently. For conflicting evaluation, an agreement was reached following discussion during a consensus meeting with a third reviewer. The following information was collected from each study: first author\'s name, year of publication, country of origin, ethnicity, control source (hospital-based or population-based), genotyping methods, and numbers of cases and controls with the XPC different genotypes distribution. The stratification analysis was conducted by ethnicity and control source.

Statistical methods
-------------------

Crude odds ratios (ORs) with their corresponding 95% CIs were used to assess the strength of association between the XPC Lys939Gln polymorphism and bladder cancer risk. The pooled ORs and 95% CIs were calculated for Lys939Gln polymorphism using homozygous model (Gln/Gln vs. Lys/Lys), heterozygous model (Lys/Gln vs. Lys/Lys), recessive model \[Gln/Gln vs. (Lys/Gln + Lys/Lys)\], dominant model \[(Lys/Gln + Gln/Gln) vs. Lys/Lys\], as well as allele comparison model (Gln vs. Lys). Pooled OR estimate of each study was calculated by both the fixed effects model (the Mantel--Haenszel method) \[[@B4]\] and the random effects model (the DerSimonian and Laird methods) \[[@B5]\]. The fixed-effects model would be adopted when the studies were found to be homogeneous (with P \> 0.10 for the Q test). Otherwise, the random-effects model would be applied. Heterogeneity between studies was evaluated by Chi square-based Q-test \[[@B6]\]. Heterogeneity was considered statistically significant if P \< 0.10. Heterogeneity was quantified using the *I*^*2*^ metric, which was independent of the number of studies in the meta-analysis (*I*^*2*^ \< 25% no heterogeneity, *I*^*2*^ = 25--50% moderate heterogeneity, and *I*^*2*^ \> 50% large or extreme heterogeneity). Subgroup analyses were performed by ethnicity and source of control to explore the reasons of heterogeneity. The funnel plot was generated to examine the potential publication bias by using the standard error of log (OR) of each investigation plotted against its log (OR), and the asymmetry of funnel plot was assessed by the method of Egger's linear regression test \[[@B7]\]. Sensitivity analyses were performed to assess the stability of the results. All statistical tests were performed with Stata (Version 12.0, Stata Corporation, College Station, TX), using two-sided P-values.

Results
=======

Study characteristics
---------------------

A total of 71 potentially relevant publications were identified from the databases listed above. After screening the titles or abstracts, 59 publications were excluded because of duplicate data, case reports, or reviews, or non-relevance research. All studies included in the present meta-analysis used a case--control design. Finally, 12 studies were identified for eligibility and were included in our meta-analysis, with a total of 4,828 cancer cases and 4,890 controls \[[@B8]-[@B19]\] (Table [1](#T1){ref-type="table"}). All patients in cases groups were histologically or pathologically confirmed, and controls were mainly matched by age, sex and ethnicity. The genotype distribution of the Lys939Gln polymorphism was in compliance with HWE in the controls of all studies.

###### 

Main characteristics of these studies on the associations between XPC Lys939Gln polymorphism and bladder cancer risk

  **First author**       **Year**   **Country**   **Ethnicity**   **Study type**   **Genotype method**   **Sample size**          **P**~***HWE***~
  ---------------------- ---------- ------------- --------------- ---------------- --------------------- ----------------- ------ ------------------
  Sanyal et al.          2004       Sweden        Caucasian       PB               PCR-RFLP              309               246    0.294
  Sak et al.             2005       England       Caucasian       HB               TaqMan                532               561    0.191
  Garcia-Closas et al.   2006       Spain         Caucasian       HB               TaqMan                1137              1138   0.470
  Wu et al.              2006       USA           Caucasian       HB               TaqMan                606               596    0.744
  Zhu et al.             2007       USA           Caucasian       HB               Taqman                550               554    0.668
  Fontana et al.         2008       French        Caucasian       HB               TaqMan                51                45     0.456
  de Verdier et al.      2010       Sweden        Caucasian       PB               PCR-RFLP              305               328    0.147
  Gangwar et al.         2010       India         Asian           HB               PCR-RFLP              208               245    0.054
  Rouissi et al.^1^      2011       Tunisia       African         HB               PCR-RFLP              193               193    0.537
  Rouissi et al.^2^      2011       Tunisia       African         HB               PCR-RFLP              125               125    0.449
  Mittal et al.          2012       India         Asian           PB               PCR-RFLP              212               250    0.073
  Liu et al.             2012       China         Asian           HB               PCR-RFLP              600               609    0.824

*PB* Population-Based Study, *HB* Hospital-Based Study, *P*~*HWE*~ P value of Hardy--Weinberg equilibrium. *PCR-RFLP* Polymorphism Chain Reaction- Restriction Fragment Length Polymorphism. *1,2* Different studies.

Meta-analysis results
---------------------

The overall results indicated that there were significant associations between all three studied XPC Lys939Gln polymorphism and increased risk of bladder cancer (Table [2](#T2){ref-type="table"}). Overall, there is statistically significant association was found between XPC Lys939Gln polymorphism and the bladder cancer risk in homozygous model (OR = 1.39, 95% CI = 1.08-1.79) (Figure [1](#F1){ref-type="fig"}), heterozygous model (Gln/Gln vs Gln/Lys: OR = 1.42, 95% CI = 1.11-1.83) (Figure [2](#F2){ref-type="fig"}), and allele comparison model (OR = 1.12, 95% CI = 1.003-1.24) (Figure [3](#F3){ref-type="fig"}), but not in other models (Table [2](#T2){ref-type="table"}). In the subgroup analysis by ethnicity, statistically significant associations were observed in African populations for homozygous model (OR = 1.758, 95% CI = 1.097-2.819), and recessive model (OR = 1.781, 95% CI = 1.057-3.002). Similarly, statistically significant associations were observed in Asian populations for homozygous model (OR = 1.476, 95% CI = 1.110-1.962), heterozygous model (Gln/Gln vs Gln/Lys: OR = 1.586, 95% CI = 1.105-2.276), and recessive model (OR = 1.489, 95% CI = 1.130-1.962). However, no statistical associations were found in Caucasian populations for other genetic models (Table [2](#T2){ref-type="table"}). In population-based populations, statistically significant associations were found for homozygous model (OR = 1.854, 95% CI = 1.338-2.569), heterozygous model (Gln/Gln vs Gln/Lys: OR = 1.806, 95% CI = 1.310 -2.491), recessive model (OR = 1.489, 95% CI = 1.130-1.962) and allele comparison model (OR = 1.233, 95% CI = 1.067-1.423), while there are no statistical associations were found in hospital-based populations for all kinds of comparison models.

###### 

Main results of pooled odds ratios (ORs) with confidence interval (CI) in the meta-analysis

  **Variables**             **No. of studies**                    **OR (95% CI)**                                          **Ph**                                    **P**                 **OR (95% CI)**     **Ph**     **P**       **OR (95% CI)**     **Ph**      **P**
  ------------------------ -------------------- --------------------------------------------------- ---------------------------------------------------- ------------------------------ --------------------- -------- ----------- --------------------- -------- -------------
  Total                             9                           1.352 (1.088 1.681)                                        0.000                                    **0.00**             1.354 (1.085 1.688)   0.001    **0.007**   1.017 (0.932 1.109)   0.592       0.712
  **Ethnicity**                                                                                                                                                                                                                                                          
  Caucasian                         3                           1.240 (0.927 1.658)                                        0.002                                     0.148               1.184 (0.913 1.536)   0.006      0.203     1.041 (0.938 1.155)   0.278       0.448
  African                           3                           1.758 (1.097 2.819)                                        0.373                                   **0.019**             1.800 (0.969 3.342)   0.196      0.063     0.955 (0.680 1.341)   0.575       0.791
  Asian                             2                           1.476 (1.110 1.962)                                        0.554                                   **0.007**             1.586 (1.105 2.276)   0.256    **0.012**   0.962 (0.802 1.154)   0.655       0.677
  **Source of controls**                                                                                                                                                                                                                                                 
  HB                                5                           1.225 (0.967 1.551)                                        0.009                                     0.093               1.233 (0.969 1.570)    0.88      0.088     1.017 (0.924 1.120)   0.382       0.728
  PB                                3                           1.854 (1.338 2.569)                                        0.958                                   **0.000**             1.806 (1.310 2.491)   0.896    **0.000**   1.013 (0.823 1.247)   0.678       0.900
  **Variables**             **No. of studies**                    **OR (95% CI)**                                          **Ph**                                    **P**                 **OR (95% CI)**     **Ph**     **P**       **OR (95% CI)**     **Ph**      **P**
                                                 **Lys/Lys vs Gln/Gln + Gln/Lys (dominant model)**   **Gln/Gln vs Gln/Lys + Lys/Lys (recessive model)**   **Gln allele vs Lys allele**                                                                            
  Total                             9                           0.945 (0.867 1.029)                                        0.397                                     0.194               1.362 (1.099 1.688)    0.18      0.18      1.109 (1.013 1.214)   0.019     **0.024**
  **Ethnicity**                                                                                                                                                                                                                                                          
  Caucasian                         3                           0.940 (0.814 1.085)                                        0.086                                     0.397               1.219 (0.934 1.591)   0.002      0.145     1.097 (0.960 1.254)   0.003       0.175
  African                           3                           0.890 (0.649 1.220)                                        0.948                                     0.468               1.781 (1.057 3.002)   0.241    **0.030**   1.258 (1.001 1.579)   0.546       0.049
  Asian                             2                           0.954 (0.803 1.133)                                        0.846                                     0.590               1.489 (1.130 1.962)   0.357    **0.005**   1.123 (0.989 1.275)   0.996       0.073
  **Source of controls**                                                                                                                                                                                                                                                 
  HB                                5                           0.962 (0.865 1.070)                                        0.264                                     0.480               1.239 (0.982 1.563)   0.003      0.071     1.078 (0.971 1.197)   0.021       0.160
  PB                                3                           0.874 (0.718 1.065)                                        0.655                                     0.183               1.824 (1.343 2.477)   0.956    **0.000**   1.233 (1.067 1.423)   0.749    **0CPA004**

*OR* Odds Ratio, *CL* Confidence Interval, *P*~*h*~ P value of heterogeneity.
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Heterogeneity analyses
----------------------

Substantial heterogeneities were observed in the overall analysis evaluating the association between XPC Lys939Gln polymorphism and bladder cancer risk in homozygous model (P = 0.000), heterozygous model (Gln/Gln vs Gln/Lys: P = 0.007), and allele comparison (P = 0.007), except for the heterozygous (Gln/Lys vs Lys/Lys: P = 0.348), dominant model (P = 0.397), and recessive model (P = 0.18).

Sensitivity analyses
--------------------

We next performed a leave-one-out sensitivity analysis to determine whether a particular study or studies would result in heterogeneity. It was found that one study \[[@B13]\] with small sample size, 51 cases and 45 controls, and obvious genotype frequency deviation may qualitatively change the pooled ORs for Lys939Gln polymorphism. After this study was dropped, the degree of heterogeneity dramatically decreased, without altering the overall estimates.

Publication bias
----------------

Begg's funnel plot and Egger's test were performed to assess the publication bias. The shape of funnel plots did not reveal any evidence of obvious asymmetry in all comparison models, and the results of Begg's test did not show any evidence of publication bias (Figure [4](#F4){ref-type="fig"}).
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Discussion
==========

It is well recognized that there is a range of individual susceptibility to the same kind of cancer even with identical environmental exposure. Host factors, including polymorphisms of genes involved in carcinogenesis, may have accounted for this difference. Therefore, genetic susceptibility to cancer has been a research focus in scientific community.

This meta-analysis, including 4,828 cancer cases and 4,890 controls from 12 published case--control studies, explored the association between the XPC Lys939Gln polymorphism and bladder cancer risk. Overall, we found that there was evidence that the variant genotypes of the XPC Lys939Gln were associated with a significant increased overall risk of bladder cancer. In the subgroup analysis based on ethnicities, significant associations were found between both African and Asian populations for some genetic models, suggesting that XPD Lys939Gln polymorphism play similar roles in populations with different genetic backgrounds and living environment. Simultaneously, our results also showed that significantly increased bladder cancer risk in homozygous, heterozygous, recessive and allele comparison models were noted in the population-based studies but not in hospital-based studies.

There are some limitations should be acknowledged in this meta-analysis. Firstly, bladder cancer is a multi-factorial disease that results from complex interactions between many genetic and environmental factors. It suggests that there will not be single gene or single environmental factor that has large effects on bladder cancer susceptibility. Secondly, in the subgroup analyses by ethnicity and source of controls, the number of subjects was relatively small, not having enough statistical power to explore the real association. Thirdly, the controls were not uniformly defined. Although most of the controls were selected mainly from healthy populations, some had respiratory disease. Therefore, non-differential mis-classification bias was possible because these studies may have included the control groups who had different risks of developing bladder cancer. Fourth, our meta-analysis is similarly with other works\[[@B20]-[@B22]\], while a more precise analysis should be conducted if individual data were available, which would allow for the adjustment by other covariates including age, sex, family history, environmental factors and lifestyle. Furthermore, other pathological type of urinary bladder cancer should be considered \[[@B23]-[@B25]\], which may be the source of publication. In addition, as in most meta-analyses, publication bias must be considered because only published studies were included in the meta-analysis.

Despite some limitations listed above, our meta-analysis had several advantages. First, sufficient number of cases and controls were pooled from different studies, which significantly increased the statistical power of the analysis. Second, no publication biases were detected, indicating that there is no bias among the pooled results.

Conclusion
==========

In conclusion, this meta-analysis indicates that XPC Lys939Gln polymorphism may be contributed to the development of bladder cancer risk. However, a study with the larger sample size is needed to further evaluated gene-environment interaction on XPC Lys939Gln polymorphism and bladder cancer risk.
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